

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

Docket No.

RLL-2011US

11/14/02

Under 37 CFR 1.97(b) or 1.97(c)

In Re Application Of: MURPANI et al.

OCT 29 2002

Serial No.  
10/085,664Filing Date  
2/27/2002Examiner  
unknownGroup Art Unit  
1619

Title: FAST DISSOLVING TABLETS OF CYCLOOXYGENASE-2 ENZYME INHIBITORS

Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

- ☐ the statement specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-201US

In Re Application: MURBANI et al.

Serial No.

10/085,664

Filing Date

2/27/2002

Examiner

unknown

Group Art Unit

1619

FAST DISSOLVING TABLETS OF CYCLOOXYGENASE-2 ENZYME INHIBITORS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited October 21, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Christine Kenedy

Typed or Printed Name of Person Mailing Certificate


\*This certificate may only be used if paying by deposit account.

Signature

Jayadeep R. Deshmukh, Esq., Reg. No. 34,507  
Ranbaxy Laboratories Limited  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Telephone: (609) 720-5608  
Facsimile: (609) 514-9779

Dated: October 21, 2002

CC:



Docket No.: RLL-201US      Serial No.: 10/085,664

Applicants: MURPANI *et al.*

Filed: February 27, 2002      Group: 1619

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**RECEIVED**  
 OCT 31 2002  
 TECH CENTER 1600/2800

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	B1	EP 0 748 628 A	12/18/96	EPO				
	B2	EP 0 945 134 A	9/29/99	EPO				X
	B3	WO 01/85134 A	11/15/01	WIPO				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.